Radioactive cancer fighter enters human testing for tough tumors
NCT ID NCT07189871
Summary
This early-stage trial is testing a new radioactive drug called 177LuBetaBart in adults with advanced solid cancers that have stopped responding to standard treatments. The study aims to find a safe dose and see if the drug shows early signs of fighting tumors. Participants will have one of several specific cancer types, including prostate, lung, breast, and ovarian cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BAMF Health
RECRUITINGGrand Rapids, Michigan, 49503, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dothan Hematology & Oncology
RECRUITINGDothan, Alabama, 36303, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
XCancer
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.